Proactive - Interviews for investors

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford discusses an NHS case study that showcases the efficacy of Creo's Speedboat technology.

In an interview with Proactive's Stephen Gunnion, Gulliford discussed the case study, which was conducted by the NHS Supply Chain responsible for the procurement of devices and consumables worth approximately £4 billion. This study, which analysed 130 cases, demonstrated significant cost savings and clinical outcomes, with almost £700,000 saved and reductions in hospital stay times for patients, which potentially impacts surgical and endoscopy waiting lists significantly.

Gulliford also outlined future plans involving routine guidance by NICE and ongoing partnerships with the NHS Supply Chain to further implement and leverage the technology across UK trusts. He emphasized the dual benefits of clinical excellence and cost savings.

Additional updates from Gulliford included progress in other areas of the company, like advancements with robotics and polymeric technology, and significant regulatory developments. Overall, these initiatives are part of Creo’s strategy to expand its product range and increase utilisation of its technology not just in the UK but globally, he added.

#CreoMedicalGroup, #NHS, #HealthcareInnovation, #MedicalTechnology, #SpeedboatTechnology, #CostSavings, #ClinicalOutcomes, #NICEGuidance, #UKHealthcare, #TechnologyInMedicine, #NHSProcurement, #MedicalDevices, #PatientCare, #HealthcareSavings, #SurgicalTechnology, #Endoscopy, #BowelCancerScreening, #ColorectalCancer, #HealthTech, #MedicalResearch #proactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with news the company has entered a significant contract with AstraZeneca, marking its second major collaboration with a large pharmaceutical company.

Newland, expressed enthusiasm about this development, noting the contract's potential to expand ANGLE's services in oncology trials. The initial phase of the contract is valued at £150,000, but it holds substantial potential due to the possibility of implementing a new assay in numerous cancer trials involving AstraZeneca. The scope of the collaboration includes the development of assays for examining proteins on cancer cells across multiple trials, with potential earnings of £2,000 per time point in over 460 trials.

The contract also enables ANGLE to further validate and possibly expand its FDA approvals, positioning it uniquely as a provider of comprehensive diagnostic solutions internationally.

Looking ahead, the successful execution of the contract could lead to extensive financial gains for ANGLE PLC, ranging into the tens or even hundreds of millions of pounds, particularly as AstraZeneca's trials progress and its drugs approach commercial launch.

#ANGLEPLC, #AstraZeneca, #Pharmaceuticals, #OncologyTrials, #CancerResearch, #ClinicalTrials, #DiagnosticSolutions, #FDAApproval, #HealthcareInnovation, #Biotechnology, #MedicalResearch, #DrugDevelopment, #PharmaPartnerships, #CancerTherapy, #LaboratoryServices, #PrecisionMedicine, #CancerDiagnostics, #CompanionDiagnostics, #RegulatoryCompliance, #PharmaNews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ilika PLC (AIM:IKA, OTCQX:ILIKF) chief executive Graeme Purdy discusses a trading update and the latest company milestones with Proactive's Stephen Gunnion.

Purdy highlighted that Ilika's financial performance for the year ending in April is expected to be in line with projections, noting a significant revenue increase from £0.8 million the previous year to approximately £2 million. This growth is largely attributed to grant support for their Goliath development programme. He provided an update on the Goliath batteries, mentioning that they had reached a milestone in late 2023, which allowed them to start producing P1 prototypes for external evaluation. These prototypes are currently being tested, with results expected to be shared with partners soon.

Additionally, Purdy touched on achieving lithium ion parity with their Goliath batteries, marking a significant technological advancement. He also discussed the progress with their Stereax product following a tech transfer and licence agreement with Cirtec in the USA, which is moving forward with the initial production line installed and operational.

Purdy said investors can participate in a Q&A session with Ilika on 26 April at 11am BST on the Investor Meet Company (IMC) platform by registering here: https://www.investormeetcompany.com/ilika-plc/register-investor

#IlikaPLC, #GraemePurdy, #ProactiveLondon, #GoliathBatteries, #LithiumIonParity, #Stereax, #TechTransfer, #Cirtec, #FinancialUpdate, #BatteryTechnology, #PrototypeDevelopment, #RevenueGrowth, #InvestorMeeting, #MarketDynamics, #CapitalMarketsDay, #EnergyDensity, #ScurveDevelopment, #MedicalDeviceMarket, #FaradayBatteryChallenge #AdvancedPropulsionCentre, #InvestorEngagement #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE hit another all-time high of 8,081 as trading got underway, following repeated record closes so far this week.

The mood was less positive for Lloyds though, as shares in the bank fell on news profits slipped in the first quarter, partially hit by a jump in costs relating to headcount reductions.

Elsewhere, consumer goods firm Reckitt Benckiser enjoyed a brighter start after reporting an increase in like-for-like sales over the first quarter.

Specialist distribution group Bunzl also climbed early on, as held profit guidance overshadowed a dip in revenue on lower volumes in the US.

And finally, Jet2 fell as stronger summer trading was eyed but profit for the year just gone was said to sit in the middle point of previous guidance.

#ProactiveInvestors #marketreport #ftse #ftse100 #footsie #lloyds #reckittbeckiser #bunzl #jet2 #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Fah Mai Holdings Group Inc UK head and manager of @whiskybullauctions Jacob Carter discusses the benefits of whisky as a stable and tangible asset in a volatile stock market environment.

In an interview with Proactive's Stephen Gunnion, Carter highlighted that whisky appreciates in value due to its age, scarcity, and availability, offering an independent performance from economic conditions. He differentiated between bottles and casks, noting bottles provide more flexibility while casks require longer investment periods without annual returns but with potential for substantial appreciation.

Carter also addressed the role of whisky in hedging against inflation, especially through supply constraints in the bottle market. He described bottles as more adaptable and easier to sell, providing liquidity to investors. In contrast, casks represent a longer-term investment but are less correlated to volatile stock movements.

He further explained Fah Mai Holdings' investment opportunities, including direct cask purchases, fractional cask investments through Platinum Cask, and Whisky Bull Auctions for trading bottles.

Carter stressed the importance of transparency, honesty, and investor education in their operations, especially as the company prepares for an IPO and undergoes independent auditing for international markets.

#FahMaiHoldings #WhiskyInvestment #JacobCarter #WhiskyBullAuctions #WhiskyAsAsset #InvestInWhisky #WhiskyMarket #CaskInvestment #WhiskyAuctions #IPOPreparation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) chief financial officer Kevin Flynn provides an update on the company's performance for the first quarter of 2024, highlighting strong results in line with expectations.

In an interview with Proactive's Stephen Gunnion, Flynn noted significant volume growth, particularly from the Kestrel operations, expected primarily in the first half of the year. Commodity prices, especially for copper, have remained robust, contributing positively to the quarter's performance.

Looking ahead, Flynn emphasised the potential for both organic growth and strategic acquisitions. Key projects like Voisey’s Bay and Mantos Blancos are expected to ramp up, with the latter seeing a debottlenecking initiative anticipated to drive further volume growth in the latter half of the year. The feasibility study for the Santo Domingo project is on track for completion in H1, and updates from BHP’s West Musgrave project are expected by August.

Flynn also highlighted the company’s significant copper asset portfolio, boosted by recent acquisitions like the $20 million Vizcachitas project, positioning Ecora for long-term growth in the copper sector. Finally, he discussed the increasing engagement with the royalty model as an alternative financing solution in the mining industry, given the current scarcity of capital from traditional sources.

#EcoraResourcesPLC #Q12024Update #CopperMarket #MiningIndustry #OrganicGrowth #StrategicAcquisitions #KevinFlynn #CFOInterview #CommodityPrices #RoyaltyModel #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

PharmAla Biotech Nick Kadysh joined Steve Darling from Proactive to share exciting developments, announcing significant milestones achieved by the company's joint venture, Cortexa Pty., in Australia. Cortexa has commenced batch manufacturing of GMP LaNeo MDMA 40mg capsules, marking an Australian first. These capsules will support both clinical trials and clinical use under the TGA's Authorised Prescriber pathway.

PharmAla's mission is twofold: to address the global shortage of clinical-grade MDMA for clinical trials and commercial sales in selected jurisdictions, and to develop novel drugs in the same class. As the sole provider of clinical-grade MDMA for patient treatments outside of clinical trials, PharmAla is uniquely positioned in the market.

According to Kadysh, Cortexa's achievement of domestic Australian manufacturing represents a significant milestone in the local psychedelic landscape. This move strengthens Cortexa's leadership position by establishing a reliable local supply, eliminating the costly and time-consuming burden of importation, and providing seamless access to medication for clinicians and researchers.

In addition to this achievement, PharmAla has successfully closed a previously announced non-brokered private placement, raising gross proceeds of $750,000. The company plans to allocate the net proceeds towards securing global patent rights for its portfolio of novel intellectual property assets, manufacturing products for sale, and funding clinical trials for its patented drug candidates.

#proactiveinvestors #pharmalabiotechholdingsinc #cse #mdma #otc #mdxxf

#NicholasKadysh, #MDMA, #Pharmaceuticals, #ClinicalTrials, #AustraliaHealthcare, #CortexJV, #Psilocybin, #FDAApproval, #BiotechIndustry, #HealthcareInnovation, #DrugDevelopment, #MDMATherapy, #Biotechnology, #MedicinalMDMA, #RegulatoryUpdates, #GlobalHealth, #PsychedelicMedicine, #TherapeuticDrugs, #ResearchAndDevelopment, #MentalHealth, #HealthcarePartnerships, #MedicalResearch, #AustralianMarket, #Biopharmaceuticals#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to share exciting updates with Proactive regarding the renewal of Master Deployment Agreements with paramedic services in Ontario. These agreements, spanning 12 months with an Ontario County Paramedic Service and 24 months with the Guelph Wellington - City of Guelph Paramedic Service, signify the continued partnership between Cloud DX and these healthcare providers.

In Ontario, Community Paramedic Services leverage Cloud DX's Connected Health Remote Patient Monitoring (RPM) services to offer daily monitoring of vital signs, physical symptoms, and chronic conditions to seniors. Through the Cloud DX mobile app, patients can interact with paramedics, facilitating close oversight and empowering patients to manage their own care effectively.

Of particular note is the Community Paramedicine for Long-Term Care (CPLTC) program, fully funded by the Ontario provincial government to provide additional care for seniors before admission into long-term care facilities. The recent announcement of an additional $174 million CAD in funding to expand the CPLTC program from 2024 onwards underscores the importance and growth potential of this initiative.

Kaul emphasized that contract renewals are a significant sales metric for Cloud DX, demonstrating the company's ability to continue serving satisfied clients effectively. Cloud DX has successfully renewed and extended Master Service Agreements with Community Paramedic Services in 10 Ontario counties, further solidifying its position as a trusted partner in the healthcare industry.

#proactiveinvestors #clouddxinc #tsxv #cdx #otc #cdxff #medical #remotemonitoring

#RemotePatientMonitoring, #HealthcareInnovation, #PatientSatisfaction, #HealthTech, #ContractRenewals, #ProvincialHealth, #CommunityParamedics, #ClinicianSupport, #HealthcareTechnology, #VirtualCare, #MedicalTech, #OntarioHealthcare, #PatientCare, #DigitalHealth, #TechInMedicine, #HealthcareSolutions, #MedicalMonitoring, #HealthAuthority, #ClinicianWorkflow, #PatientCompliance, #HealthTechInnovation, #HealthcareContracts, #HealthcareTrends, #TechDrivenHealthcare

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lisata Therapeutics CEO David J. Mazzo discusses the oncology company's focus and recent advancements in an interview with Proactive's Stephen Gunnion.

Lisata Therapeutics, established 18 months ago through the acquisition of Cend Therapeutics by Caladrius Biosciences, is dedicated to developing technologies aimed at treating solid tumour cancers. The company's primary product, certepetide (LSTA1) is a nine amino acid cyclic peptide designed to target and penetrate tumours. It is used in combination with chemotherapy and other cancer treatments.

Currently, the most advanced programme targets metastatic pancreatic ductal adenocarcinoma, with phase 2B results expected later this year.

Lisata has also received several orphan drug designations, including for pancreatic cancer, glioblastoma, and osteosarcoma. Additionally, it has a rare paediatric disease designation for osteosarcoma in the US.

Mazzo highlighted discussions with regulatory authorities in Australia, the EMA, and the FDA about potential accelerated approval based on upcoming trial results. He expressed optimism about commercializing List-1 as early as 2026 under ideal conditions.

Investors can look forward to various clinical and data milestones in the next 12 to 18 months, including potential business development activities.

#LisataTherapeutics #Oncology #CancerResearch #FDAApproval #ClinicalTrials #OrphanDrugDesignation #PancreaticCancer #Glioblastoma #Osteosarcoma #BiotechNews #HealthcareInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

First Phosphate Corp CEO John Passalacqua and Chief Geologist Gilles Laverdiere joined Steve Darling from Proactive to announce the third set of assay results from its ongoing 25,000 metres drill program at the Bégin-Lamarche project in Quebec. With a total of 23,398 meters drilled, assays from 9,155 meters have been completed, while 4,691 samples are still pending at the laboratory.

The latest positive results include significant intersections in various zones of the project. In the Phosphate Mountain Zone, drill hole BL-24-56 intersected 11.82% P2O5 over 92.5 meters from a surface depth of 6.5 meters. This zone exhibits a thick layer of phosphate-bearing nelsonite outcropping on the surface, with several other high-grade intersections exceeding 10% P2O5. The Phosphate Mountain Zone is merging with the Northern Zone, which has delineated a 500-meter-thick phosphate mineralized envelope containing up to five individual layers ranging from 60 to 100 meters in thickness. The combined strike length of the Phosphate Mountain Zone and the Northern Zone is approximately 600 meters.

In the Northern Zone itself, drill hole BL-24-40 intersected 7.76% P2O5 over 88.2 meters from a depth of 186.0 meters, including 9.33% P2O5 over 61.2 meters. Positive results were also observed in the Northwestern Zone and Southern Zone, indicating the project's robust mineralization potential across multiple areas.

#proactiveinvestors #firstphosphatecorp #phosphate #BéginLamarcheproject #CEOInterview

#MiningNews, #PhosphateMining, #ResourceDevelopment, #DrillingUpdate, #JohnPassalacqua, #GillesLaverdière, #MiningTechnology, #QuebecMining, #SustainableResources, #MiningIndustry, #Geology, #EconomicAssessment, #InvestorInsights, #CorporateMining, #EnergyMaterials, #ResourceEstimation, #MineralExploration, #MiningInnovation, #IndustrialMinerals, #PhosphateRock, #CanadianMining, #ExplorationGeology, #MiningOperations, #StrategicMinerals#CompanyUpdate #StrategicGrowth #SustainableMining #GreenApproach

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews